Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10881086
Genetically modified mouse whose genome comprises a humanized CD274 gene
granted -
US 10875911
High affinity human antibodies to human angiopoietin-2
granted -
US 10863729
Rodents having a humanized TMPRSS gene
granted -
US 10865236
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
granted -
US 10857231
Formulations of VEG antagonist fusion proteins and method of manufacturing them
granted -
US 10857205
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 10851158
Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof
granted -
US 10844137
Anti-CTLA-4 antibodies and uses thereof
granted -
US 10829544
Human antibodies to Ebola virus glycoprotein
granted -
US 10828345
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 10815305
Methods of treating inflammatory conditions
granted -
US 10806780
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
granted -
US 10793624
Human antibodies to Bet v 1 and methods of use thereof
granted -
US 10785966
Humanized M-CSF mice
granted -
US 10785968
Genetically modified non-human animals and methods of use thereof
granted -
US 10787501
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
granted -
US 10787647
HSD17B13 variants and uses thereof
granted -
US 10774128
IL-33 antagonists and uses thereof
granted -
US 10772972
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
granted -
US 10772956
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted -
US 10765762
Humanized model of kidney and liver disorders
granted -
US 10752690
Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
granted -
US 10752702
Anti-TIE2 antibodies and uses thereof
granted -
US 10752701
Stabilized formulations containing anti-PCSK9 antibodies
granted